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550Recovery of CMV-Specific CD81 T Cells and Tregs after
Allogeneic Peripheral Blood Stem Cell Transplantation
Domenico Pastore, Mario Delia, Anna Mestice, Tommasina Perrone, Paola Carluccio,
Francesco Gaudio, Annamaria Giordano, Antonella Russo Rossi, Alessandra Ricco,
Manuela Leo, Vincenzo Liso, Giorgina Specchia1Recovery of cytomegalovirus (CMV)-specific CD8 T cells after allogeneic stem cell transplantation (SCT) is
critical for protection against CMV infection and disease. Moreover, Foxp31CD41CD25high regulatory
T cells (Tregs) are a major regulator of adaptive immunity, preventing graft-versus-host disease (GVHD)
and so promoting timely and complete immune recovery. The aim of our study was to evaluate the recovery
of circulating tetramer-based CMV-specific CD81 T cells and Tregs in 46 patients after allogeneic peripheral
blood SCT (PBSCT). CMV infection and/or disease was observed in 7% and 94% of patients with or without
CMV-specific CD81 T cells recovery (P\.001), and in 77% and 4% of patients with or without acute GVHD
(aGVHD) (P\.001), respectively. Tregs values were higher in patients without than with CMV infection and/
or disease at 2 (P\ .001) and 3 months (P\ .001) after allogeneic PBSCT, respectively. Moreover, we
observed a positive correlation between T regs and the recovery of CMV-specific CD81 T cells at 2
(r 5 .61, P\.0001) and 3 (r 5 .72, P\.00001) months, respectively. Tregs were higher in patients without
than with aGVHD at 1, 2 (P\.001) and 3 months (P\.0001), respectively. At multivariate logistic regression,
aGVHD (odds ratio [OR]: 2.60, 95% confidence interval [CI] [1.3-5.0], P 5 .0006) and CMV-specific CD81
T cells recovery (OR:2.25, 95% CI [1.2-4.8], P 5 .05) were correlated with CMV infection and/or disease,
whereas no correlation was found for Tregs, absolute neutrophil count, patients’ and donors’ age, disease
status pretransplantation, type of disease, and CMV serology. Taken together, our data may suggest the
existence of a correlation between Tregs and the recovery of CMV-specific CD81T cells; Tregs may preserve
an optimal microenvironment for the reconstitution of functional immunity and mediate protective effects
against aGVHD.
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Despite the recent development of potent antiviral
medication, reactivation of cytomegalovirus (CMV) is
one of the major complications in patients undergoing
allogeneic stem cell transplantation (SCT), and is
significantly related to morbidity and mortality rates
[1-3]. The decision to administer antiviral therapy is
currently based on the clinical risk [4,5] and the
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[6,7]. However, prolonged treatment with antiviral
drugs, such as gancyclovir and foscarnet, increases
the risk of other infectious complications because of
myelotoxicity [8], and impairs the reconstitution of
CMV-specific CD81 T cell responses, thereby in-
creasing the risk for late CMV disease [9]. Recovery
of CMV-specific CD81 T cells plays an important
role in the control of CMV reactivation [10,11], and
monitoring their number [12-14] may be crucial to
optimize the antiviral therapy with minimal drug
exposure.
Moreover, Foxp31CD41CD25high regulatory
T cells (Tregs) are major regulators of adaptive immu-
nity [15] and, given the pathophysiologic link between
graft-versus-host disease (GVHD) and immune recon-
stitution [16,17], protection against GVHD by Tregs
could potentially promote timely and complete
immune recovery [18]. Depletion of Tregs enhances
microbial and tumor immunity [19], whereas their
adoptive transfer protects animals from autoimmune
Biol Blood Marrow Transplant 17:550-557, 2011 551Tregs and CMV-Specific Immune Recovery in Allogeneic PBSCTdisease [15], induces tolerance following organ trans-
plantation and prevents early GVHD in SCT models
[20-22]. GVHD damages the stroma of the thymus
and secondary lymphoid organs, thereby decreasing
thymic output, impairing the peripheral expansion of
T cells, and consequently leading to a prolonged
immunodeficiency state [16,17]. However, the
impact of Tregs on host immunity after allogeneic
SCT is still poorly understood. In this study, we
investigated the recovery both of Tregs and of
tetramer-based CMV-specific CD81T cells after allo-
geneic peripheral blood SCT (PBSCT).PATIENTS, MATERIALS, AND METHODS
Forty-six patients who underwent allogeneic
PBSCT between February 2005 and September 2008
were included in this study (Table 1); written informed
consent was obtained from all patients. Patients’
characteristics are shown in Table 1. As conditioning
regimen, all patients received a conventional myeloa-
blative regimen that included 16 mg/kg of oral busul-
fan and 120 mg/kg of cyclophosphamide. All patients
were administered prophylactic antibiotics (levofloxa-
cin 500 mg daily) until neutrophil engraftment; we
used fluconazole (400 mg daily to day 100) as antifun-
gal prophylaxis and trimethoprim-sulfamethoxazole
for Pneumocystis carinii prophylaxis.
All patients received GVHD prophylaxis, using
cyclosporine A (starting on day 21) and methotrexate
(on days 11, 13, 16, 111). Heparinized blood sam-Table 1. Patient Characteristics
N %
Patients 46
Sex (male/female) 25/21 54/46
Median age: years (range) 36 (13-61)
Diagnosis
Acute myelogenous leukemia 39 85
Acute lymphoblastic leukemia 4 9
Chronic myelogenous leukemia 2 4
Myelofibrosis 1 3
CMV serological status recipient/donor
Positive/positive 40 87
Positive/negative 4 9
Negative/positive 2 4
Conditioning regimen
Busulfan + cyclophosphamide 46 100
Donor
HLA matched sibling 46 100
Median age, years (range) 40 (23-56)
Disease status pretransplant
CR 36 78
Not CR 10 22
Source of stem cells
PBSC 46 100
GVHD prophylaxis
CsA + MTX 46 100
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cells;
GVHD, graft-versus-host disease; CsA, cyclosporin; MTX, methotrex-
ate; CR, complete remission.ples were taken at 1, 2, 3, and 6 months after transplan-
tation for the cytometric Tregs, CMV-specific CD81
T cells, and absolute neutrophil counts. Tregs evalua-
tion was also performed in those patients with acute
GVHD (aGVHD), at its precise onset, before starting
any treatment for aGHVD, during the period from
0 to 3 months after allogeneic PBSCT. The HLA ge-
notype was HLA-A01 in 6 patients, HLA-A02 in 23
patients, HLA-B01 in 1 patient, HLA-B02 in 2 pa-
tients, and HLA-B35 in 14 patients. Tregs evaluation
was also performed in 24 of 46 (52%) donor grafts.
Foxp31CD41CD25high Regulatory T Cells
(Tregs) Count
Cells were phenotypically analyzed by flow cytome-
try using a panel of directly conjugated antibodies to
CD3, CD4, CD25 (M-A251), and CD45RO. Fluores-
cein isothiocyanate (FITC), phycoerythrin (PE), PercP,
and allophycocyanin (APC) were used as fluorophores
(Beckman Coulter, Miami, FL, USA; and Becton
Dickinson, Franklin Lakes, NJ, USA). Intracellular
analysis of FoxP3 (eBioscience, San Diego, CA, USA)
was performed after fixation and permeabilization
according to the manufacturer’s recommendations.
Flow cytometry was performed by a flow cytometer
(FACS Calibur, Becton Dickinson) and data were
acquired and analyzed using Cellquest software.
Tetramer Staining
We used fluorochrome-conjugated tetrameric
complexes of CMVpp50245-253 VTEHDTLLY-HLA-
A0101, CMVpp65495-503 NLVPMVATV-HLA-A
0201, CMVpp65417-426 TPRVTGGGAM-HLA-B
0702, IE-1199-207 ELRRKMMYM-HLA-B0801, and
CMVpp65123-131 IPSINVHHY-HLA B3501 to mon-
itor recovery of CMV-specific CD81 T cells (accord-
ing to the patients’ HLA); 5 mL CD8-FITC, CD3-P5,
CD4-P5, CD19-P5, and CD13-P5 and 2 mL
fluorochrome-conjugated tetrameric HLA (according
to the patients’ HLA) purchased from Beckman Coul-
ter Inc., were added to 100 mL heparinized blood and
incubated for 30 min. After the RBC were lysed and
washed twice, the cells were fixed and acquired on
a flow cytometer (FACS Calibur, Becton Dickinson).
More than 20000 cells in the lymphocyte gate were
acquired and analyzed using Cellquest software. The
CD42, CD192, CD132 and CD31, CD81 CMV-
tetramer positive fraction of the lymphocyte gate was
defined as CMV-specific CD81 T cells.
Preventing CMV Infection and Disease
CMV seropositivity was assessed by the detection
of IgG antibodies to CMV late antigen. CMV recipi-
ent/donor serologic status is shown inTable 1; no neg-
ative/negative serologic status was found in our case
study. All patients received prophylactic high-dose
552 Biol Blood Marrow Transplant 17:550-557, 2011D. Pastore et al.acyclovir 500 mg/m2 intravenously 3 times daily, fol-
lowed by 800 mg orally (when feasible) 4 times daily,
throughout the period from engraftment to 100 days
after allogeneic PBSCT [6]. During this time, patients
underwent viral monitoring by CMV pp65 antigen
(Ag) in peripheral blood leukocytes (PBLs) (CMVBrite
Immunofluorescence kit BiotestDiagnostics,Denville,
NJ, USA) once a week and received preemptive antivi-
ral therapy if evidence of CMV replication was found
[6]. Following this period, patients who had experi-
enced CMV reactivation or had severe GVHD contin-
ued to bemonitored weekly, whereas the other patients
were monitored every 2 weeks. CMV disease was
defined according to Ljungman et al [23].Figure 1. Box plots showing values of circulating CMV-specific CD81
T cells at 1, 2, 3, and 6 months after allogeneic peripheral blood stem cell
transplantation in patients with (CMV1) and without (CMV2) CMV in-
fection/disease. The top, bottom, and middle lines through the box cor-
respond to the 75th, 25th, and 50th percentiles, respectively. The bars
on the bottom and top extend from the bottom 10th percentile and
top 90th percentile, respectively.Preemptive Antiviral Therapy
On detection of CMV pp65 Ag in PBLs, preemp-
tive therapy was started [6]. The initial therapy was
ganciclovir 5 mg/kg twice per day for a minimum of
7-14 days, which was then adjusted according to the
follow-up CMV antigenemia value [6].CMV-Specific Immune Response Recovery
Reconstitution of CMV-specific CD81 T cells, as
evaluated by quantitative tetramer to levels.10/mL, was
considered adequate for protection against CMV infec-
tion [11,12,14,24,25]. Receiver operating characteristic
(ROC) curve analysis was performed to define the
threshold number of CMV-specific CD81 T cells in
association with a CMV pp65 Ag-positive test.Acute aGVHD Treatment
All patients were treated with methylprednisolone
at doses of 2 mg/kg body weight, which were then
adjusted according to clinical improvement or not.Table 2. Correlation between CMV Infection/Disease and
CMV-Specific Immune Recovery, acute GVHD, or Absolute
Neutrophil Count (ANC)
CMV-Specific IR+(%) CMV-Specific IR2(%) P*
2 (7) 16 (94) <.001
aGVHD+ (%) aGVHD2 (%)
17 (77) 1 (4) <.001
ANC < 500/mL (%) ANC $ 500/mL (%)
9 (37) 9 (41) Ns
aGVHD indicates acute graft-versus-host disease; CMV, cytomegalovi-
rus; ANC, absolute neutrophil count.
Patients with CMV-specific immune recovery (IR+); without CMV-
specific IR (IR2); with acute GVHD (aGVHD+); without aGVHD
(aGVHD2); No. of patients IR+: 29; No. of patients aGVHD+: 22; No.
of patients with <500 ANC/mL: 24.
*Fisher’s Exact test.Statistical Analysis
The Mann-Whitney Rank Sum test was used for
comparison of absolute cell counts between 2 groups,
and Kruskal-Wallis One Way Analysis of Variance
on Ranks test for multiple comparisons versus the
control group (Dunn’s Method). Fisher’s exact test
(2-sided) was performed to compare proportions, and
the Pearson product for correlation. Logistic regres-
sion was performed for univariate and multivariate
analysis.RESULTS
CMV Infection
CMV antigenemia was positive in 18 of 46 (39%)
patients, between day 28 and day 93 (median, day 47)
after transplantation, 3 of 46 (6%) patients developed
CMV disease (2 pneumonitis, 1 colitis) and died.
CMV infection was controlled in 2 of 2 (100%) and
in 5 of 16 (31%) patients with and without recovery
of CMV-specific CD81 T cells, respectively.Table 3. Median CMV-Specific CD8+ T Cells and Tregs at Any
Time Point
Median CMV-Specific
CD8+ T Cells (r) Median Tregs (r)
with CMV
infection
w/o CMV
infection
with
aGVHD
w/o
aGVHD
1 mo. 0 (0-3) 2 (0-5) 5 (0-7) 10 (0-14)
2 mo. 0 (0-4) 5 (0-9) 6 (0-9) 15 (4-18)
3 mo. 1 (0-8) 12 (5-23) 6 (2-9) 19 (8-38)
6 mo. 3 (0-5) 22 (5-53) 7 (3-10) 21 (9-41)
CMV indicates cytomegalovirus; aGVHD, acute graft-versus-host disease;
mo, month; r, range; w/o, without.
Figure 2. Receiver operating characteristic (ROC) curve of CMV-
specific CD81 T cells for antigenemia CMV diagnostic test; area under
curve: 0.985 (95% CI: 0.894-1.000). The performance is summarized in
Table 3.
Biol Blood Marrow Transplant 17:550-557, 2011 553Tregs and CMV-Specific Immune Recovery in Allogeneic PBSCTA second episode of CMV reactivation occurred in
2 of 18 (11%) patients. CMV infection/disease corre-
lation with CMV-specific immune recovery, aGVHD,
and absolute neutrophil count is shown in Table 2.
CD41, CD81, and CMV-Specific CD81 T Cell
Counts
The median value of CD41 T cells was 110/mL
(range: 30-380), 160 (range: 43-430), 209 (range:
40-420), and 346 (range: 80-450) at 1, 2, 3, and 6
months, respectively. The median value of CD81
T cells was 280/mL (range: 130-456), 454 (range: 159-
1230), 573 (range: 174-1692), and 722 (range: 482-
2242) at 1, 2, 3, and 6 months after allogeneic PBSCT,
respectively. The median value of CD41 and CD81
showed no difference in patients with and without
CMV infection/disease. Median CMV-specific CD81
T cells were significantly higher in patients without
than with CMV infection/disease at 1 (2 cells/mL versus
0,P\ .001), 2 (5 cells/mLversus 0,P\ .001), 3 (12 cells/
mL versus 1,P\ .001), and 6months (22 cells/mL versus
3, P\ .001), respectively (Figure 1 and Table 3), withTable 4. Diagnostic Performance of CMV-Specific CD8+ T Cells Va
Criterion Sensitivity 95% CI Spec
<0 0.00 0.0-17.6 10
#4 78.95 54.4-93.9 10
#5* 89.47 66.9-98.7 9
#7 89.47 66.9-98.7 9
#8 94.74 74.0-99.9 8
#9 100.00 82.4-100.0 8
#23 100.00 82.4-100.0
CI indicates confidence interval; CMV, cytomegalovirus; +LR: positive likelihoo
Criterion: CMV-specific CD8+ T cells.a progressive increase of CMV-specific CD81 T cells
as from the first month in patients without CMV infec-
tion/disease (Figure 1).We did not find any correlation
betweenCD341 stem cells andT cell graft contentwith
T cells recovery.
By ROC analysis, a CMV-specific CD81 T cells
value of #5/mL is associated with a pp65 Ag CMV-
positive test (Figure 2 and Table 4).
Tregs Evaluation
The median Tregs values at any time point are
summarized in Table 3; they were significantly higher
in patients without than with CMV infection/disease
at 2 (15/mL versus 3, P \ .001, Figure 3A) and 3
months (22/mL versus 6, P\ .001, Figure 3B) after al-
logeneic PBSCT. Moreover, we observed a good cor-
relation between Tregs and recovery of CMV-specific
CD81T cells at 2 (r5 .61, P\ .0001) (Figure 4A) and
3 (r 5 .72, P\ .00001) (Figure 4B) months, respec-
tively.
aGVHD
aGVHD was observed in 22 of 46 patients (48%).
Median time of aGVHD onset was 50 days (range: 33-
77). Tregs were significantly higher in patients without
than with aGVHD (Figure 5).
Tregs Graft Content (Evaluation Performed on
24 of 46 [52%] Donor Grafts)
Tregs graft content counts was higher in patients
who did not develop aGVHD compared with those
who did (12 versus 2 cells 106/kg, P \ .001)
(Figure 6).
Univariate and Multivariate Logistic Regression:
Impact on CMV Infection and/or Disease
Data are summarized in Tables 5 and 6.
Relapse and Survival Rate
Relapse and overall survival (OS) rates did not dif-
fer between patients with or without CMV-specific
immune recovery, whereas OS rate is significantly dif-
ferent in patients with or without aGVHD (Table 7).lues
ificity 95% CI +LR 2LR
0.00 86.8-100.0 1.00
0.00 86.8-100.0 0.21
6.15 80.4-99.9 23.26 0.11
2.31 74.9-99.1 11.63 0.11
8.46 69.8-97.6 8.21 0.059
0.77 60.6-93.4 5.20 0.00
0.00 0.0-13.2 1.00
d ratio; 2LR: negative likelihood ratio. *, optimal diagnostic point.
Figure 3. Box plots showing values of circulating T regs in patients with (CMV1) and without (CMV2) CMV infection/disease at 2 (A) and 3
months (B).
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Despite major advances in the diagnosis and treat-
ment of infectious complications in transplantation
patients, CMV infection/disease remains a major cause
of treatment-related morbidity and mortality after
allogeneic SCT [1-3]. Protective immunity toward
CMV is maintained by CMV-specific CD81 T cellsFigure 4. Correlation between Tregs and CMV-specific CD81 T cells.
Dots correspond to samples from patients undergoing allogeneic pe-
ripheral blood stem cell transplantation after 2 (A) and 3 (B) months.
A significant positive correlation was seen between Tregs and CMV-
specific CD81 T cells, as shown by the trend line (A, r 5 .61;
P\.0001; B, r 5 .72; P\.00001).[10,11]. Additionally, naturally arising CD41CD251
regulatory T cells are major regulators of adaptive
immunity [15] and, in amurineGVHDmodel, adoptive
transfer of Tregs leads to improved immunity to CMV,
with a significant reduction in viral load and increased
survival [18]. In our experience, in a homogeneously
treated population (busulfan and cyclophosphamide,
and HLA-matched sibling donor transplantation in
46 of 46 patients [100%]), we observed a correlation be-
tween increasedTregs and protection against CMVat 2
and 3months after allogeneic PBSCT (Figures 3 and 4).
So far, little is known about the contribution of
Tregs to protective immunity against CMV and, conse-
quently, to the number of circulating CMV-specific
CD81 T cells. Particularly, immunity against CMV
may be altered by GVHD status [16,17] and related
functional defects [26,27]. Thus, evaluation of the
CMV-specific immune response, regardless of GVHD
status, might appear to have a limited value for estimat-
ing its real contribution to lower CMV infection risks.
Nevertheless, in accordance with other authors
[12-14], we believe that monitoring CMV-specific
CD81 T cells may help to identify the risk of CMV
infection/disease after allogeneic SCT. Functional
depression of the lymphocytes because of GVHD, cor-
ticosteroids, or other immunosuppressive therapy for
GVHD seems to be the major cause of CMV reactiva-
tion after allogeneic SCT [4,26,27], although theFigure 5. Median value of circulating T regs in patients with aGVHD
(aGVHD1) compared with those without aGVHD (aGVHD2) at 1,
2, and 3 months.
Figure 6. Median value of graft Tregs content in patients with aGVHD
(aGVHD1) and without aGVHD (aGVHD2).
Table 6. Multivariate Logistic Regression: Impact on CMV
Infection/Disease
Variables Odd Ratio (95% CI) P
aGVHD (grade II-IV)
Yes/no 2.60 (1.30, 5.00) .006
CMV-specific CD8+ T cells recovery
No/yes 2.25 (1.20, 4.30) .05
Tregs 2.35 (0.90, 5.50) .06
aGVHD indicates acute graft-versus-host disease; CI, confidence
interval; CMV, cytomegalovirus.
Biol Blood Marrow Transplant 17:550-557, 2011 555Tregs and CMV-Specific Immune Recovery in Allogeneic PBSCTinfluence of corticosteroids on reconstitution of CD81
T cells is controversial. Some studies [11,14] have
reported a significant reduction of CMV-specific
CD81 T cells with corticosteroid therapy. Evidence
from another study [26] has indicated that the frequency
and the absolute number of these cells were similar in
patients receiving corticosteroids and those who did
not, whereas CMV-specific CD81T cells showed a de-
creased cytokine production, suggesting a qualitative
rather than a quantitative alteration [26]. In any case,
our data confirm the correlation of CMV infection/dis-
ease with both graft status and CMV specific immune
response (Tables 2, 5, and 6).
Some authors [24,25,27] have reported that it is
difficult to predict CMV infection by the evaluation
of CMV-specific T cell reconstitution using HLA
tetramer assays as these do not correlate with the inci-
dence and severity of CMV infection and/or disease.
Conversely, we and other authors [12-14] have
shown that the numeric reconstitution of CMV-Table 5. Univariate Logistic Regression: Impact on CMV
Infection/Disease
Variables Odd Ratio (95% CI) P
aGVHD (Grade II-IV)
Yes/No 2.65 (1.40, 4.75) .001
CMV-specific CD8+ T cells recovery
No/yes 2.60 (1.35, 4.80) .001
Tregs 2.35 (1.06, 5.00) .03
ANC
<500 mL/$500 mL 1.30 (0.70, 3.10) .30
Patient age 1.00 (0.95,1.05) .75
Donor age 1.01 (0.96, 1.04) .55
Disease status pretransplantation
Remission/not remission 2.05 (0.84, 4.70) .10
Diagnosis
Myeloyd/not myeloid malignancy 1.10 (0.70, 2.10) .84
CMVserology
High risk/not high risk 1.45 (0.65, 3.30) .30
CMV indicates cytomegalovirus; CI, confidence interval; ANC, absolute
neutrophil count.
Donor type: 100% sibling.
Conditioning regimen intensity: 100% full ablative.
Transplant source: 100% PBSC.specific immune response after allogeneic SCT may
be protective against the development of CMV
infection/disease (Figure 1). Moreover, the best sensi-
tivity and specifity threshold number of CMV-specific
CD81 T cell for CMV Ag positive test (Figure 2 and
Table 4) is below the one considered protective against
CMV replication [11,12,14,24,25]. Therefore, close
monitoring of CMV-specific CD81Tcells, in a cohort
of patients early after transplantation, could constitute
a rapid and sensitive tool to identify allogeneic SCT
recipients at risk for developing CMV infection and/
or disease. It should be noted that 46 of 46 (100%)
of our patients must be considered at risk and 4 of 46
(9%) at high risk for CMV reactivation in view of the
donor/recipient CMV serologies [4-6]. Moreover, it
has been demonstrated [28] that short courses of anti-
viral treatment allow a rapid reconstitution of CMV-
specific CD81T cells in most patients, at least in those
given a transplant from a CMV-seropositive donor
(42/46 of our cases). Therefore, although few studies
[11,12,14,24,25] have reported thresholds of T cell
immunity that can be considered protective against
CMV and the only pilot study [29] using T cell re-
sponses as the guide for withholding antiviral therapy
was for patients more than 100 days after SCT, we
consider that close monitoring of CMV specific
CD81 T cells may enable us to distinguish those pa-
tients who might benefit from short courses of pre-
emptive antiviral therapy from the ones who mightTable 7. Correlation between Relapse and Overall Survival
with CMV-Specific Immune Recovery or aGVHD
CMV-Specific IR+ CMV-Specific IR2
Relapse incidence @ 34 versus 35*
Overall survival rate @ 72 versus 65*
aGVHD+ aGVHD2
Relapse incidence @ 27 versus 42*
Overall survival rate @ 82 versus 58†
CMV indicates cytomegalovirus; aGVHD, acute graft-versus-host
disease.
@: % at 2 years; Log Rank test.
Patients with CMV-specific immune recovery (IR+); without CMV-
specific IR (IR2); with aGVHD (aGVHD+); without aGVHD (aGVHD2).
*P 5 ns.
†P 5 .04.
556 Biol Blood Marrow Transplant 17:550-557, 2011D. Pastore et al.avoid treatment while monitoring viral replication, if
CMV-specific CD81T cells are detectable. Moreover,
although a preemptive treatment strategy is highly
effective at managing CMV infection [7], late presen-
tation of CMV disease can occur [9,30], and this has
a high mortality rate [3].
Several studies [20-22,31] have demonstrated that
Tregs suppress GVHD in animal models. This is
consistent with our experience, in which higher levels
of Tregs are associated with the absence of aGVHD
(Figure 5). Moreover, it has been demonstrated [32]
that increased numbers of Tregs are associated with
chronic GVHD (cGVHD), indicating that cGVHD
does not occur as a result of a deficiency of these cells.
Patients with a profound immune dysregulation occur-
ring more than 100 days after allogeneic SCT do not
seem to benefit by Tregs [32] as much as early after
transplantation [33]. Particularly in this early phase, as
demonstrated in murine models, Tregs contribute to
protect from GVHD lethality [20,22], preserve thymic
and peripheral lymph node architecture, and promote
an accelerated donor lymphoid reconstitution, which
can bemore effective againstCMV [18]. In a clinical set-
ting, soonafter allogeneicSCT,Tregsmayprotect from
aGVHD in humans [33] and, not only as a consequence
of less immunosuppressive therapies, fromCMVreacti-
vation. This is consistent with the correlation we found
between Tregs and protection against CMV in the
early phase after transplantation (Figures 3 and 4). Of
note, the median time of CMV reactivation and
aGVHD was 47 and 50 days, respectively. This
quite contemporary onset could suggest that Tregs,
although they act through different mechanisms, drive
both CMV-specific CD81 recovery and protection
against GVHD. Moreover, the Tregs graft content is
significantly lower in patients with aGVHD than in
those without aGVHD (Figure 6), confirming the thy-
mic preservation by Tregs.
In conclusion, we suggest that there is a good
correlation between the recovery of Tregs and of
CMV-specific CD81 T cells; Tregs mediate the pro-
tective effects against aGVHD and the maintenance
of an optimal microenvironment for the reconstitution
of functional immunity. This supports further consider-
ation of Tregs immunotherapy for clinical allogeneic
SCT. Particularly, adoptive transfer of Tregs may be
useful, with the aim of abrogating ongoing aGVHD
and promoting a more rapid immune reconstitution
in patients at risk of CMV infection and/or disease.ACKNOWLEDGMENTS
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